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Abstract 
 
Virus genome sequence variants that appear over the course of an outbreak can be exploited to 
map the trajectory of the virus from one susceptible host to another. While such variants are 
usually of no functional significance, in some cases they may allow the virus to transmit faster, 
change disease severity, or confer resistance to antiviral therapies. Since the discovery of SARS-
CoV-2 as the cause of COVID-19, the virus has spread around the globe, and thousands of 
SARS-CoV-2 genomes have been sequenced. The rate of sequence variation among SARS-
CoV-2 isolates is modest for an RNA virus but the enormous number of human-to-human 
transmission events has provided abundant opportunity for selection of sequence variants. 
Among these, the SARS-CoV-2 Spike protein variant, D614G, was not present in the presumptive 
common ancestor of this zoonotic virus but was first detected in late January in Germany and 
China. The D614G variant steadily increased in frequency and now constitutes >97% of isolates 
world-wide, raising the question whether D614G confers a replication advantage to SARS-CoV-
2. Structural models predict that D614G would disrupt contacts between the S1 and S2 domains 
of the Spike protein and cause significant shifts in conformation. Using single-cycle vectors we 
showed that D614G is three to nine-fold more infectious than the ancestral form on human lung 
and colon cell lines, as well as on other human cell lines rendered permissive by ectopic 
expression of human ACE2 and TMPRSS2, or by ACE2 orthologues from pangolin, pig, dog, or 
cat. Nonetheless, monoclonal antibodies targeting the receptor binding domain of the SARS-CoV-
2 Spike protein retain full neutralization potency. These results suggest that D614G was selected 
for increased human-to-human transmission, that it contributed to the rapidity of SARS-CoV-2 
spread around the world, and that it does not confer resistance to antiviral therapies targeting the 
receptor binding domain. 
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Introduction 
 
Next-generation sequencing permits real-time detection of genetic variants that appear in 
pathogens during disease outbreaks. Tracking viral variants now constitutes a requisite 
component of the epidemiologist’s toolkit that may pinpoint the origins of a zoonotic virus and the 
trajectory it takes from one susceptible host to another (Hadfield et al., 2018; Shu and McCauley, 
2017). Lagging behind sequence-based modeling of virus phylogeny and transmission chains is 
the ability to understand the effect of viral variants on the efficiency of transmission to new hosts 
or on the clinical severity of infection. Most sequence variants that arise during virus replication 
are either detrimental to the fitness of the virus or without consequence. Even so, such variants 
can increase in frequency over the course of an outbreak  by chance (Grubaugh et al., 2020). 
More rarely, though, increasing frequency of a variant could reflect competitive advantage due to 
higher intrinsic replication capacity with increased viral load and transmissibility. 
In December 2019, an outbreak of unexplained fatal pneumonia became apparent in 
Wuhan City, Hubei Province, China. By early January 2020, SARS-CoV-2 was identified as the 
virus causing the disease (Huang et al., 2020; Lu et al., 2020; Wu et al., 2020a, 2020b; Zhou et 
al., 2020b; Zhu et al., 2020). After SARS-CoV (Drosten et al., 2003; Ksiazek et al., 2003) and MERS-
CoV (Zaki et al., 2012), SARS-CoV-2 is the third human coronavirus this century known to cause 
pneumonia with a significant case-fatality rate (Coronaviridae Study Group of the International 
Committee on Taxonomy of Viruses, 2020). Hundreds of coronaviruses have been identified in 
bats, including at least 50 SARS-like Sarbecoviruses (Lu et al., 2020; Zhou et al., 2020a). The 
virus closest in sequence to SARS-CoV-2 observed to date was isolated from a bat (Zhou et al., 
2020b) though the most proximal animal reservoir for SARS-CoV-2 remains unknown (Andersen 
et al., 2020; Lam et al., 2020). 
Over the course of the SARS-CoV-2 pandemic, there have been reports of super-
spreaders and transmission chains that have been more difficult to interrupt in some locations 
than in others (Hu et al., 2020). As few as 10% of SARS-CoV-2 infected people account for the 
majority of virus transmission events (Endo et al., 2020). Reported case fatality rates have varied 
by more than 10-fold (Center for Systems Science and Engineering at Johns Hopkins University; 
COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, 
Korea Centers for Disease Control and Prevention, 2020; Grasselli et al., 2020; Onder et al., 
2020). Such differences may reflect regional differences in the age of susceptible populations or 
the prevalence of comorbidities such as hypertension. Regional variation in diagnostic testing 
frequency, or in rate of reporting, is another likely explanation for these differences, since a wider 
net of diagnostic testing will capture milder cases (Zhao et al., 2020). Understanding the cause of 
these observed differences is critical for rational utilization of limited medical resources to 
counteract the pandemic. 
Coronaviruses have the largest genomes of any known RNA viruses (Saberi et al., 2018) 
and they encode a 3’-to-5’-exoribonuclease required for high-fidelity replication by the viral RNA-
dependent RNA polymerase (Denison et al., 2011; Smith et al., 2014). By preventing otherwise 
lethal mutagenesis (Smith et al., 2013) the repair function of the coronavirus exonuclease is 
thought necessary for the coronavirus genome size to extend beyond the theoretical limit imposed 
by error rates of viral RNA polymerases (Holmes, 2003). Though the rate of sequence variation 
among SARS-CoV-2 isolates is modest, over the course of the pandemic the virus has had 
opportunity to generate sequence variants, many of which have been identified among the 
thousands of SARS-CoV-2 genomes posted for public access (https://www.gisaid.org/) (Hadfield 
et al., 2018). 6,754 unique single nucleotide polymorphisms have been identified from high-quality 
sequence data, 99.4% of which are within viral gene sequences and 64% of these encode amino 
acid changes (Phelan et al., 2020). Here we investigate the potential consequences of one of 
these variants, the Spike protein variant D614G. 
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Results and Discussion 
 
Over the course of the COVID-19 pandemic, the SARS-CoV-2 D614G S protein variant 
supplanted the ancestral virus 
SARS-CoV-2 genomes sequenced from the earliest COVID-19 cases had minimal genetic 
variation. This suggests that they were recent descendants of a common ancestor that gave rise 
to all SARS-CoV-2 genomes seen during the outbreak (Rambaut et al., 2020). At the end of 
January 2020, a nonsynonymous nucleotide change from the ancestral virus, A23403G, first 
appeared in virus genomes reported in China (hCoV-19/Zhejiang/HZ103/2020; 24 January 2020) 
and in Germany (hCoV-19/Germany/BavPat1-ChVir929/2020; 28 January 2020). This nucleotide 
change encodes the spike (S) protein variant D614G. Although these sequences suggest that the 
D614G variant first emerged in China or Germany, given how few virus genomes have been 
sequenced from early in the outbreak, its geographic origin cannot be determined. 
Since its first appearance, the frequency of the D614G variant has increased steadily over 
time in the global SARS-CoV-2 genomic dataset released by GISAID, to the point that it is nearly 
fixed in the viruses sampled globally (Figure 1A) or specifically in Europe, North America, 
Oceania, and Asia (Figure 1B). The D614G variant emerged at higher frequency in Africa and 
South America, suggesting a founder effect where a plurality of introductions carried D614G to 
these regions. Although recent data for South America are sparse, available sequences suggest 
D614G is approaching fixation in this continent as well. 
Over the course of the whole pandemic, the D614G variant is present in approximately 
74% of published sequences (Figure 1A). It should be noted, however, that the roughly 53,000 
high-quality SARS-CoV-2 genomic sequences available from GISAID as of 25 June 2020, are a 
narrow snapshot of the global pandemic, approximately 0.5% of the 9.611M cases confirmed as 
of the same date (Dong et al., 2020). Analysis of D614G variant frequency is expected to gain 
resolution as sequences are released for samples banked across the duration of the pandemic. 
While understanding will improve around the historical trajectory of its ascendence to fixation, the 
D614G variant is now universally common on every continent except Antarctica. 
The SARS-CoV-2 Spike protein variant D614G, then, was not present in the common 
ancestor of the sampled isolates but has risen to high frequency across many regions. This raises 
the question whether D614G confers a selective replication advantage to SARS-CoV-2, or 
whether it may explain regional differences in rates of death or other clinical parameters. 
Answering this question will require correlation with rates of transmission through populations, or 
with disease outcome, in combination with detailed assessment of its effects on viral biochemistry 
and replication, some of which are examined in experiments described below. To date, more 
severe disease outcome with D614G has not been reported, but several studies suggest that it is 
associated with a modest increase in viral load (Korber et al., 2020; McNamara et al., 2020; 
Wagner et al.). 
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Figure 1. Frequency of the 
SARS-CoV-2 S protein D614G 
variant over the course of the 
COVID-19 pandemic.  
The frequency of the S protein 
D614G variant over time in 
sequences published via the 
GISAID SARS-CoV-2 database, 
as of 25 June 2020. (A) Global 
dataset: The filled plot (blue) 
represents a 7-day rolling 
average of the fraction of 
sequences bearing the D614G 
variant for each collection date. 
Dates without published 
sequences are linearly 
interpolated. The cumulative 
frequency of the D614G variant 
(black line) is overlaid, showing 
the frequency of D614G in 
sequences from samples 
collected up to and including 
each date.  (B) The frequency of 
the D614G variant over time 
(blue) in sequences collected 
from six continental regions, 
plotted as a 7-day rolling 
average. Frequencies are 
interpolated for dates without 
published sequence. The 
frequency of the last date with 
data is carried forward where 
recent dates lack data to indicate 
the most recent calculated 
frequency (light blue). The 
number of samples collected, 
sequenced, and published is 
overlaid (red bars) to provide the 
denominator used in calculating 
the frequency for each date, and 
to illustrate the non-uniformity of 
sampling. 
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The SARS-CoV-2 D614G S protein variant increases infectivity 
The ability of the SARS-CoV-2 D614G S protein variant to target virions for infection of ACE2-
positive cells was assessed using single-cycle lentiviral vector pseudotypes in tissue culture. 
Mammalian expression plasmids were engineered to encode the ancestral S protein (D614) and 
the D614G variant, as described previously (Moore et al., 2004). Each S protein expression 
plasmid was separately transfected into HEK-293 cells with plasmids encoding HIV-1 structural 
proteins and enzymes. Separate plasmids were transfected that encode RNAs with HIV-1 cis-
acting signals for packaging and replication, and either GFP or luciferase (Luc) reporter cassettes. 
For each condition tested, multiple virus stocks were produced and tested individually after vector 
particle normalization using reverse transcriptase activity. 48 hours after challenge with the 
vectors, the transduction efficiency of each virion preparation was assessed by measuring the 
percent GFP-positive cells by flow cytometry, or by target cell-associated luciferase activity. 
When Calu-3 human lung epithelial cells were used as targets, challenge with lentivirus 
bearing D614G resulted in 6-fold more GFP-positive cells, or 5-fold more bulk luciferase activity, 
than did particles bearing D614 S protein (Figure 2). When Caco-2 human colon epithelial cells 
were used as the target cells 4-fold higher infectivity was observed with D614G (Figure 2). 
Additionally, when HEK-293 cells or SupT1 cells had been rendered infectable by stable 
expression of exogenous ACE2 and TMPRSS2, D614G was 9-fold more infectious than D614 
(Figure 2). 
 
 
 
Figure 2. SARS-CoV-2 D614G S protein variant enhances infectivity 
Lentiviral virions bearing either GFP or Luciferase transgenes, and pseudotyped with either SARS-CoV-2 
D614 or D614G S proteins, were produced by transfection of HEK293 cells, and used to transduce human 
Calu3 lung cells, Caco2 colon cells, and either HEK293 or SupT1 cells stably expressing ACE2 and 
TMPRSS2. Relative infectivity of D614G vs D614, with D614 set at 1, was determined based on flow 
cytometry for percent GFP-positivity or bulk luciferase activity. Each point represents transduction with a 
lentiviral stock that was derived from an independent transfection. Shown are the mean +/- SD. 
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Effect of D614G on infectivity of different ACE2 orthologues 
If SARS-CoV-2 Spike D614G is an adaptive mutant that was selected for increased human-to-
human transmission following spillover from an animal reservoir, increased infectivity might only 
be evident on cells bearing ACE2 orthologues similar to that of the human. A SARS-like 
coronavirus isolated from a horseshoe bat (Rhinopholus sp.), with 96% identity along the whole 
virus genome and 93% in the S protein coding sequence, has the greatest sequence similarity to 
SARS-CoV-2 (Zhou et al., 2020b). Nonetheless, the most proximal source of the SARS-CoV-2 
zoonosis remains unknown. Structural and biochemical studies (Letko et al., 2020; Walls et al., 
2020; Wrapp et al., 2020; Zhou et al., 2020b) show that SARS-CoV-2 has a receptor binding 
domain with high affinity for ACE2 from humans, ferrets, cats, and other species that encode 
ACE2 with high homology (Wan et al., 2020). In a heterologous expression system on HeLa cells, 
human, civet, horse-shoe bat (Rhinolophus sinicus), and pig orthologs conferred susceptibility to 
infection, while the mouse ortholog did not (Zhou et al., 2020b). 
As a first step to examine whether the increased infectivity of D614G is species-specific, 
plasmids were generated to express ACE2 orthologues from human (Homo sapiens), Malayan 
pangolin (Manis javanica), pig (Sus scrofa), cat (Felis catus), dog (Canis lupis), rat (Rattus 
norvegicus), and mouse (Mus musculus). HEK-293 were transfected separately with each of the 
ACE2 expression plasmids and challenged with luciferase-reporter-lentiviral pseudotypes bearing 
SARS-CoV-2 Spike protein, either D614 or D614G. Relative increase in infectivity due to D614G 
was comparable in cells expressing human, pangolin, pig, cat, or dog ACE2 orthologues (Figure 
3). The relative effect of D614G on infectivity using cells bearing rat or mouse ACE2 orthologues 
could not be determined since in both cases the luciferase activity with D614 was not clearly 
above background. Examination of D614G infectivity using ACE2s encoded by other mammalian 
species may provide further insight into the structure and function of this Spike variant.  
 
Figure 3. SARS-CoV-2 D614G S protein variant enhances infectivity on ACE2 orthologues 
Lentiviral virions bearing Luciferase transgenes, and pseudotyped with either SARS-CoV-2 D614 or D614G 
S proteins, were produced by transfection of HEK293 cells, and used to transduce human HEK293 cells 
transiently transfected with plasmids encoding the indicated ACE2 orthologues. Relative infectivity of 
D614G vs D614, with D614 set at 1, was determined based on bulk luciferase activity. Each point represents 
transduction using lentiviral stock derived from an independent transfection. Shown are the mean +/- SD. 
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D614G is sensitive to neutralization by monoclonal antibodies targeting the 
receptor binding domain 
The global spread and enhanced infectivity of the SARS-CoV-2 D614G variant raises the question 
of whether this change in Spike protein structure may compromise the effectiveness of antiviral 
therapies targeting that protein. To determine if this is the case, the neutralization potency was 
assessed of four monoclonal antibodies that target the SARS-CoV-2 Spike protein receptor 
binding domain. These fully human monoclonals are currently under evaluation in clinical trials 
(NCT04425629, NCT04426695) as therapeutics for COVID-19 (Hansen et al., 2020). As seen in 
Figure 4, all monoclonal antibodies tested, individually or in combinations, demonstrated similar 
neutralization potency against both SARS-CoV-2 Spike protein variants. As all four of these 
monoclonal antibodies bind epitopes within the Spike protein receptor binding domain, it remains 
important to determine whether the D614G variants changes neutralization sensitivity to other 
classes of anti-Spike monoclonal antibodies. 
 
 
Figure 4. Neutralization potency of monoclonal antibodies targeting SARS-CoV-2 Spike protein 
variants. Vero cells were challenged with pVSV-SARS-CoV-2-S-mNeon pseudoparticles encoding either 
(A) 614D or (B) 614G spike variants, in the presence of serial dilutions of the indicated anti-Spike 
monoclonal antibodies or IgG1 isotype control. mNeon protein fluorescence was measured 24 hours post-
infection as a read-out for virus infectivity. Data is graphed as percent neutralization relative to virus only 
infection control. (C) Neutralization potency (IC50) of individual monoclonals and of monoclonal 
combinations against the 614G and 614D variants, is indicated. 
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Modeling the effect of D614G on structure 
Structures of the soluble trimeric S protein ectodomain in pre-fusion conformations demonstrate 
that the receptor-binding domains (RBD) of each protomer can independently adopt either a 
“down” position or an “up” position, giving rise to asymmetric trimer conformations (Walls et al., 
2020; Wrapp et al., 2020). Previous structural studies of SARS-CoV S and MERS-CoV S 
identified similar conformations (Gui et al., 2017; Pallesen et al., 2017; Walls et al., 2019; Yuan 
et al., 2017). These studies suggested that only upon transition of an RBD to the up position is 
the protomer capable of binding the ACE2 receptor. Models of coronavirus S-mediated membrane 
fusion describe ACE2 binding to all three RBD domains in the up position as destabilizing the pre-
fusion S trimer, leading to dissociation of S1 from S2 and promoting transition to the post-fusion 
conformation (Pallesen et al., 2017; Walls et al., 2019). Thus, the up position likely reflects an 
intermediate conformation that is on-pathway to S-mediated membrane fusion. 
The structures of SARS-CoV-2 S (Walls et al., 2020; Wrapp et al., 2020) predict that D614 
of a protomer with RBD in the up position forms a stabilizing contact with T859 of the neighboring 
protomer (Figure 2). Specifically, the delta-O of D614 in the up protomer is within hydrogen-
bonding distance (2.7A) of the gamma-O of T859 of the neighboring protomer. The other two 
inter-protomer distances for D614-T859 are 3.4A and 4.4A, suggesting that the electrostatic 
interaction may be labile and only form during transition to the up conformation. It is predicted that 
the D614G variant would abrogate this interaction and destabilize the inter-protomer interface. 
 
Figure 5. SARS-CoV-2 S protein variant D614G is predicted to disrupt an inter-protomer hydrogen 
bond with T859. 
(A) The cryo-EM structure of SARS-CoV-2 S in an asymmetric conformation. The single protomer in the up 
conformation is shown in blue cartoon representation. The two protomers in the down position are shown 
in grey surface representations (PDB: 6VSB).  
(B) Blow-up showing the predicted stabilizing electrostatic interaction between the delta-O of D614 of the 
up protomer (blue) and the gamme-O of T859 of the neighboring down protomer (grey). O atoms are shown 
in red. The inter-atomic distance of 2.7A, which is within the H-bonding distance, is shown in red. The 
D614G mutant would remove this electrostatic interaction. 
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Methods 
Analysis of D614G frequency in published data 
The frequency of the SARS-CoV-2 D614G S protein variant in published genomic data was 
examined using the full Nextstrain-curated set of sequences available from GISAID as of 25 June 
2020 (Hadfield et al., 2018; Shu and McCauley, 2017). Sequences were aligned to the ancestral 
reference sequence (NCBI GenBank accession NC_045512.2) using mafft v7.464 (Katoh and 
Standley, 2013) with the "--keeplength" and "--addfragments" parameters, which preserve the 
coordinate space of the reference sequence. To remove lower-quality sequences from the 
dataset, all sequences in the alignment were masked with ambiguous bases ('N') in the regions 
spanning the first 100bp and the last 50bp, as well as at error-prone sites located at the (1-
indexed, NC_045512.2 coordinate space) positions 13402, 24389, 24390. Sequences shorter 
than 28kb or with >2% ambiguous bases were removed from the alignment. The frequency of 
D614G was calculated in the resulting data by extracting the sequence region corresponding to 
the gene for the S protein, spanning 21563-25384bp. These sequences were processed using a 
script importing biopython (Cock et al., 2009) to remove any gaps introduced by the alignment 
process and translate the sequence to protein space. The identity of the variant at amino acid 
position 614 was tabulated for the full dataset and reported as frequency by date using the 
collection dates reported in the Nextstrain-curated metadata file available from GISAID (Hadfield 
et al., 2018; Shu and McCauley, 2017). The frequency was calculated as (# sequences with 
D614G)/(# sequences). Frequency within the six continental regions was calculated based on the 
"region" geographic classification associated with each sample in the metadata. Frequency 
values were linearly interpolated for dates surrounded by valid data. The frequency of the last 
date with data was carried forward where recent dates lack data. The resulting values were 
rendered as plots using matplotlib (Hunter, 2007). The script for analyzing and plotting D614G 
variant frequency is available via GitHub: 
https://gist.github.com/tomkinsc/c3fa656b0c833db6d3a2c579b74dcc4f 
 
Plasmids 
The plasmids used here were either previously described or generated using standard cloning 
methods. The full list of plasmids used here, along with their purpose and characteristics, is 
provided in Table 1. All newly engineered plasmids are available, along with full sequences, at 
https://www.addgene.org/Jeremy_Luban/. 
 
Cell culture 
All cells were cultured in humidified incubators with 5% CO2 at 37º C, and monitored for 
mycoplasma contamination using the Mycoplasma Detection kit (Lonza LT07-318). HEK293 cells 
(ATCC CRL-1573), and HEK-293T cells (CRL-3216 or CRL-3216) were cultured in DMEM 
supplemented with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 20 mM GlutaMAX, 1× 
MEM non-essential amino acids, and 25 mM HEPES, pH 7.2. Calu3 cells (ATCC HTB-55) were 
maintained in EMEM supplemented with 10% FBS. Caco2 cells (ATCC HTB-37) were maintained 
in EMEM supplemented with 20% FBS. SUP-T1 [VB] cells (ATCC CRL-1942) were cultured in 
RPMI supplemented with 10% heat-inactivated FBS, 1mM sodium pyruvate, 20mM GlutaMAX, 
1xMEM non-essential amino acids, and 25 mM HEPES, pH7.2. Vero cells (ATCC CCL-81) were 
cultured in DMEM high glucose media containing 10% heat-inactivated fetal bovine serum, and 
1X Penicillin/Streptomycin/L-Glutamine.  
 
Virus production 
24 hrs prior to transfection, 6 × 105 HEK-293 cells were plated per well in 6 well plates. All 
transfections used 2.49 µg plasmid DNA with 6.25 µL TransIT LT1 transfection reagent (Mirus, 
Madison, WI) in 250 µL Opti-MEM (Gibco). 
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Single-cycle HIV-1 vectors pseudotyped with SARS-CoV-2 Spike protein, either D614 or 
D614G, were produced by transfection of either HIV-1 pNL4-3 Δenv Δvpr luciferase reporter 
plasmid (pNL4-3.Luc.R-E-), or pUC57mini NL4-3 Δenv eGFP reporter plasmid, in combination 
with the indicated Spike expression plasmid, at a ratio of 4:1. 
ACE2 expression vectors were produced by transfecting cells with one of the 
pscALPSpuro-ACE2 plasmids, along with the HIV-1 gag-pol expression plasmid psPAX2, and the 
VSV glycoprotein expression plasmid pMD2.G (4:3:1 ratio of plasmids).. 16 hrs post-transfection, 
culture media was changed. Viral supernatant was harvested 48 hours after media change, 
passed through a 0.45 µm filter, and stored at 4ºC. TMPRSS2 expression transfer vector was 
produced similarly but with pscALPSblasti-TMPRSS2. 
 
Exogenous reverse transcriptase assay 
5 µL transfection supernatant was mixed with 5 µL 0.25% Triton X-100, 50 mM KCl, 100 mM Tris-
HCl pH 7.4, and 0.4 U/µL RiboLock RNase inhibitor, and then diluted 1:100 in 5 mM (NH4)2SO4, 
20 mM KCl, and 20 mM Tris-HCl pH 8.3. 10 µL of this was then added to a single-step, RT-PCR 
assay with 35 nM MS2 RNA (IDT) as template, 500 nM of each primer (5’-
TCCTGCTCAACTTCCTGTCGAG-3’ and 5’-CACAGGTCAAACCTCCTAGGAATG-3’), and 0.1 
µL hot-start Taq DNA polymerase (Promega, Madison, WI) in 20 mM Tris-Cl pH 8.3, 5 mM 
(NH4)2SO4, 20 mM KCl, 5 mM MgCl2, 0.1 mg/ml BSA, 1/20,000 SYBR Green I (Invitrogen), and 
200 µM dNTPs in total 20 µL reaction. The RT-PCR reaction was carried out in a Biorad CFX96 
real-time PCR detection system with the following parameters: 42ºC for 20 min, 95ºC for 2 min, 
and 40 cycles [95ºC for 5 sec, 60ºC for 5 sec, 72ºC for 15 sec, and acquisition at 80ºC for 5 sec]. 
  
Transduction with lentiviral vectors 
HEK-293 cells expressing ACE2 and TMPRSS2: 2.5 x 105 cells were plated per well in a 12 well 
plate. The next day cells were transduced with 250 uL of supernatant containing TMPRSS2-
encoding lentivirus for 16 hr at 37°C, after which fresh media was added to cells. 48 hrs after 
transduction cells were replated and selected with blasticidin (InvivoGen, catalogue #ant-bl-1) at 
10 ug/ml. After selection, cells were transduced similarly with supernatant containing ACE2-
encoding lentivirus and selected with 1 ug/mL of puromycin (InvivoGen, San Diego, CA, catalogue 
#ant-pr-1). 
SupT1 cells expressing ACE2 and TMPRSS2: 1 x 106 SupT1 cells were transduced with 400 uL 
of supernatant containing TMPRSS2-encoding virus followed by selection with 10 ug/mL 
blasticidin 48 hrs later. TMPRSS2 expressing SupT1 cells were then transduced with a second 
vector expressing ACE2, followed by puromycin selection at 1 ug/mL.  
 
Virus Infectivity Assays 
16 hours prior to transduction, adherent cells were seeded in 96 well plates. HEK-293 cells were 
plated at 5 x 104 cells per well. Calu3 and Caco2 were plated at 3 x 104 per well. Cells were 
incubated in virus-containing media for 16 hrs at 37°C when fresh medium was added to cells. 48 
to 72 hours after transduction cells were assessed for luciferase activity or for GFP by flow 
cytometry. For transfection of SupT1 cells, 1 x 105 cells were plated in a U-bottom 96 well plate 
and spinfected at 30oC with 100 uL of virus-containing media for 2 hours at 1,200 x g. Fresh media 
was added after spinfection and cells were incubated 48-72 hours prior to analysis. Cells 
transduced with GFP virus were fixed with BD Cytofix (BD Biosciences, San Jose, CA, Cat 
number 554655) and analyzed using the Accuri C6system. Data was analyzed using FlowJo 10.5 
(FlowJo, LLC, Ashland, OR). Cells transduced with luciferase expressing virus were assessed 
using Promega Steady-Glo system (Promega Madison, WI) 
 
 
Generation of VSV pseudoparticles and neutralizations assays 
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VSV-SARS-CoV-2-S pseudoparticle generation and neutralization assays were performed as 
previously described (Baum et al., 2020; Hansen et al., 2020). HEK293T cells were seeded 
overnight in DMEM high glucose media (Life Technologies) containing 10% heat-inactivated fetal 
bovine serum (Life Technologies), and Penicillin/- Streptomycin-L-Glutamine (Life Technologies). 
The following day, Spike expression plasmids were transfected with Lipofectamine LTX (Life 
Technologies) following the manufacturer’s protocol. At 24 hours post transfection, the cells were 
washed with phosphate buffered saline (PBS) and infected at an MOI of 1 with the 
VSVΔG:mNeon/VSV-G virus diluted in 10 mL Opti-MEM (Life Technologies). The cells were 
incubated 1 hour at 37°C with 5% CO2. Cells were washed three times with PBS to remove 
residual input virus and overlaid with DMEM high glucose media (Life Technologies) with 0.7% 
Low IgG BSA (Sigma), sodium pyruvate (Life Technologies), and Gentamicin (Life Technologies). 
After 24 hours at 37° C with 5% CO2, the supernatant containing pseudoparticles was collected, 
centrifuged at 3,000 x g for 5 minutes to clarify, aliquoted, and frozen at -80° C. For neutralization 
assays, Vero cells were seeded in 96-well plates 24 hours prior to assay and grown to 85% 
confluence before challenge. Antibodies were diluted in DMEM high 3 glucose media containing 
0.7% Low IgG BSA (Sigma), 1X Sodium Pyruvate, and 0.5% Gentamicin (this will be referred to 
as “Infection Media”) to 2X assay concentration and diluted 3-fold down in Infection Media, for an 
11-point dilution curve in the assay beginning at 10 ug/mL (66.67 nM). pVSV-SARS-CoV-2-S 
pseudoparticles were diluted 1:1 in Infection Media for a fluorescent focus (ffu) count in the assay 
of ~1000 ffu. Antibody dilutions were mixed 1:1 with pseudoparticles for 30 minutes at room 
temperature prior to addition onto Vero cells. Cells were incubated at 37° C, 5% CO2 for 24 hours. 
Supernatant was removed from cells and replaced with 100 uL PBS, and fluorescent foci were 
quantitated using the SpectraMax i3 plate reader with MiniMax imaging cytometer. 
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